Young colorectal cancer patients tend to present with acute, relatively vague symptoms and advanced disease, according to a single-centre study from Singapore.
Two Swedish national registry studies presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 suggest no increased cancer risk for rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs (bDMARDs), including tumour necrosis factor (TNF) inhibitors.
The experimental targeted therapy, enasidenib, an oral selective inhibitor of mutated IDH2 enzymes developed for the treatment of acute myeloid leukaemia (AML), has demonstrated maturation of blasts to neutrophils with resultant prolongation of survival in treatment-resistant patients with mutant-IDH2 AML in an early trial.
The second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) dacomitinib improved progression-free survival (PFS) by an additional 5 months compared with gefitinib in patients with EGFR-positive non-small cell lung cancer (NSCLC), according to results of the open-label, phase III ARCHER 1050* trial.
Selective internal radiation therapy (SIRT) did not fare better than sorafenib in terms of overall survival (OS) in patients with locally advanced hepatocellular carcinoma (HCC), though it appeared to be associated with fewer total adverse events, according to findings of the phase III, multicentre (11 Asia-Pacific countries), open-label SIRveNIB* study.